Pfizer Inc. (PFE) Stock Analysis
Pfizer Inc. (NYSE: PFE) is one of the world's largest biopharmaceutical companies, discovering and manufacturing drugs across vaccines, internal medicine, oncology, and rare diseases. Investors research Pfizer for its diversified product portfolio, dividend yield, and exposure to both established treatments and emerging therapies.
Get a full AI research report on PFE
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Pfizer Inc. do?
Pfizer generates revenue by discovering, developing, manufacturing, and distributing biopharmaceutical products globally across three operating segments: Biopharma, PC1, and Pfizer Ignite. The company's portfolio includes blockbuster brands like Eliquis (cardiovascular), Prevnar (vaccines), Vyndaqel (rare disease), and oncology immunotherapies, along with Paxlovid for COVID-19 treatment. Revenue is derived from both established drugs with recurring demand and newer therapies in high-growth therapeutic areas.
Bull case
- ✓Forward P/E ratio of 9.55 suggests the stock is trading at a significant discount to its current earnings multiple of 36.39, indicating market expectations for earnings growth or valuation expansion.
- ✓Dividend yield of 6.22% is substantially higher than the broader market average, providing income-focused investors with regular cash returns.
- ✓Gross margin of 74.7% demonstrates strong pricing power and manufacturing efficiency across the drug portfolio, supporting profitability even amid competitive pressures.
- ✓Diversified product pipeline spanning vaccines, oncology, rare diseases, and internal medicine reduces dependence on any single therapeutic area or drug.
- ✓Operating margin of 27.9% reflects operational leverage and the high-margin nature of pharmaceutical manufacturing once drugs reach market.
Bear case
- ✗Debt-to-equity ratio of 74.25 indicates substantial leverage, which limits financial flexibility and increases vulnerability to interest rate changes and credit market stress.
- ✗Current ratio of 1.27 and quick ratio of 0.85 suggest tighter short-term liquidity, with quick assets covering less than 85% of current liabilities.
- ✗PEG ratio of 12.56 is elevated relative to forward earnings growth expectations, raising questions about whether current valuation is justified by growth prospects.
- ✗Net profit margin of 6.8% is modest for a pharmaceutical company, indicating that much of gross profit is consumed by R&D, regulatory, and distribution costs.
- ✗Return on equity of 5.01% and return on assets of 5.78% are relatively low, suggesting the company generates limited profit per dollar of shareholder capital or assets deployed.
PFE valuation & financial health
Pfizer trades at a current P/E of 36.39 but a forward P/E of 9.55, signaling the market is pricing in meaningful earnings growth or near-term headwinds. The company's 6.22% dividend yield is attractive for income investors, though a payout ratio of 226% indicates dividends exceed net income—a pattern sometimes seen in mature pharma companies managing cash returns. With a gross margin of 74.7% and operating margin of 27.9%, Pfizer demonstrates strong operational profitability, but a debt-to-equity ratio of 74.25 and modest ROE of 5.01% reflect heavy leverage and capital-intensive operations. The quick ratio of 0.85 warrants monitoring for liquidity management.
The bottom line
Pfizer presents a mixed financial profile that investors should evaluate carefully. The forward P/E discount relative to the trailing multiple, combined with a high dividend yield, may appeal to value and income-oriented investors, but the elevated debt load, low return on equity, and high PEG ratio warrant consideration of the company's ability to sustain growth and service obligations. Key factors to monitor include pipeline advancement in oncology and rare diseases, patent expirations on legacy drugs, interest rate impacts on debt servicing, and execution on cost management initiatives.
Frequently asked questions
What does Pfizer Inc. do?
Pfizer discovers, develops, manufactures, and distributes biopharmaceutical products globally. Its portfolio includes vaccines (Prevnar, Abrysvo), cardiovascular drugs (Eliquis), oncology therapies, rare disease treatments (Vyndaqel), and COVID-19 treatment (Paxlovid) across three operating segments.
Is Pfizer stock overvalued or undervalued?
Pfizer's forward P/E of 9.55 is substantially lower than its trailing P/E of 36.39, suggesting the market expects earnings growth or near-term normalization. A PEG ratio of 12.56 is elevated, which some investors interpret as expensive relative to growth expectations, while others view the forward multiple as attractive if growth materializes.
What is Pfizer's dividend yield?
Pfizer's dividend yield is 6.22%, significantly above the S&P 500 average, making it attractive for income-focused investors. However, the payout ratio of 226% indicates dividends exceed reported net income, a pattern that requires monitoring for sustainability.
What are the main risks for Pfizer stock?
Key risks include high leverage (debt-to-equity of 74.25), patent expirations on legacy drugs, modest returns on equity (5.01%), tight short-term liquidity (quick ratio 0.85), and dependence on pipeline success in oncology and rare diseases to drive future growth.
How profitable is Pfizer?
Pfizer has a gross margin of 74.7% and operating margin of 27.9%, reflecting strong pricing power and operational efficiency. However, net profit margin of 6.8% and ROE of 5.01% are modest, indicating significant costs for R&D, regulation, and distribution consume much of gross profit.
Is Pfizer financially stable?
Pfizer has substantial debt (74.25 debt-to-equity ratio) and a quick ratio of 0.85, indicating moderate leverage and tighter short-term liquidity. The company's strong operating margins and cash generation support debt servicing, but investors should monitor leverage trends and interest rate exposure.
Research PFE with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.